Drug profile · INN
rozanolixizumab-noli
RYSTIGGO
rozanolixizumab-noli (RYSTIGGO) is a igg receptor fcrn large subunit p51 inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — rozanolixizumab-noli
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
rozanolixizumab-noli (RYSTIGGO) is a igg receptor fcrn large subunit p51 inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
IgG receptor FcRn large subunit p51 inhibitor
Primary target: IgG receptor FcRn large subunit p51
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is rozanolixizumab-noli?
rozanolixizumab-noli (RYSTIGGO) is a igg receptor fcrn large subunit p51 inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for rozanolixizumab-noli?
RYSTIGGO is a marketed brand name for rozanolixizumab-noli. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rozanolixizumab-noli?
rozanolixizumab-noli has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.